+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors Market by Indication (Bladder Cancer, Head And Neck Cancer, Melanoma), Mechanism Of Action (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End User, Route Of Administration - Global Forecast 2025-2030- Product Image
Immune Checkpoint Inhibitors Market by Indication (Bladder Cancer, Head And Neck Cancer, Melanoma), Mechanism Of Action (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End User, Route Of Administration - Global Forecast 2025-2030- Product Image
Sale

Immune Checkpoint Inhibitors Market by Indication (Bladder Cancer, Head And Neck Cancer, Melanoma), Mechanism Of Action (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End User, Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888905
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immune Checkpoint Inhibitors Market is undergoing rapid transformation, driven by scientific innovation, evolving treatment paradigms, and shifts in global regulatory and reimbursement environments. Senior leaders require robust, actionable intelligence to navigate these dynamics and optimize their strategies in this competitive oncology segment.

Market Snapshot: Immune Checkpoint Inhibitors Growth Trajectory

The immune checkpoint inhibitors market grew from USD 10.46 billion in 2024 to USD 11.64 billion in 2025. It is expected to continue growing at a CAGR of 10.91%, reaching USD 19.48 billion by 2030. This trajectory reflects strong momentum in oncology care, as checkpoint inhibitors become embedded in standard therapeutic protocols across a diverse range of malignancies.

Scope & Segmentation

This report provides a comprehensive assessment of the immune checkpoint inhibitors market, segmenting by indication, mechanism of action, end user, route of administration, region, and leading companies:

  • Indications: Bladder cancer, head and neck cancer, melanoma (first and second line), non-small cell lung cancer (first and second line, with monotherapy and combination therapy), and renal cell carcinoma.
  • Mechanisms of Action: CTLA-4 inhibitors (ipilimumab), PD-1 inhibitors (cemiplimab, nivolumab, pembrolizumab), and PD-L1 inhibitors (atezolizumab, avelumab, durvalumab).
  • End Users: Hospitals, specialty clinics, ambulatory surgical centers, and cancer research institutes.
  • Routes of Administration: Intravenous and subcutaneous delivery.
  • Regions: Americas (including United States states such as California, Texas, New York, Florida, and more, plus Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, and select Middle Eastern and African countries), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, and key regional markets).
  • Companies: Merck & Co., Inc., Bristol-Myers Squibb Company, Roche Holding AG, AstraZeneca PLC, Pfizer Inc., Merck KGaA.

Key Takeaways for Strategic Decision-Makers

  • Combination regimens leveraging immune checkpoint inhibitors with other pluripotent agents or precision therapies are shaping the direction of clinical development and driving differentiated value in oncology pipelines.
  • Biomarker integration, such as tumor mutational burden and PD-L1 expression, is refining patient stratification, advancing personalized approaches, and supporting adaptive trial models in both early- and late-stage clinical studies.
  • Expansion into earlier lines of treatment and additional tumor indications is redefining care pathways and challenging legacy therapeutic algorithms, with shifts observed in major cancer types.
  • Regional differences in market access, infrastructure maturity, and reimbursement processes are creating distinct commercialization challenges and opportunities across developed and emerging economies.
  • Collaborative strategies—such as partnerships between biopharma innovators, contract research organizations, and digital health specialists—are enhancing operational capacity, leveraging real-world evidence, and enabling robust market validation.
  • Technological advancements in digital pathology and artificial intelligence are being harnessed to accelerate trial recruitment and optimize immune profiling, influencing clinical uptake and operational excellence.

Tariff Impact on the Immune Checkpoint Inhibitors Market

The anticipated introduction of United States import tariffs in 2025 poses significant supply chain and pricing implications for checkpoint inhibitor manufacturers. Increased duties on crucial biopharma inputs could elevate production costs, prompt manufacturing shifts, and potentially delay product availability, influencing payer negotiations and patient access. Companies are assessing localization strategies and advocating for policy solutions to address expected disruptions in the supply and pricing of next-generation immunotherapies.

Methodology & Data Sources

This market analysis utilizes a dual approach, blending qualitative interviews with key opinion leaders—including clinical oncologists and pharmaceutical executives—and quantitative modeling of adoption curves, trial enrollment, and sensitivity assessments. Supplementary data were drawn from industry publications, regulatory agency updates, and real-world patient registries to ensure comprehensive, bias-reduced insights.

Why This Report Matters

  • Enables C-level executives to anticipate scientific, regulatory, and commercial shifts, supporting informed R&D and commercialization strategies.
  • Empowers stakeholders with comparative insights across mechanisms, segments, regions, and companies, aiding resource allocation and portfolio prioritization.
  • Guides investment and partnership decisions by elucidating pipeline innovation, access trends, and operational risks relevant to immune checkpoint inhibitor therapy.

Conclusion

Senior leaders can leverage this report to navigate the complexities of the global immune checkpoint inhibitors market, optimize decision-making, and sustain competitive differentiation in a rapidly evolving oncology landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of bispecific checkpoint inhibitors targeting PD-1 and LAG-3 to overcome resistance in solid tumors
5.2. Emerging role of microbiome modulation strategies to enhance checkpoint inhibitor efficacy in melanoma patients
5.3. Discovery of novel genomic biomarkers driving personalized PD-L1 inhibitor therapies in non small cell lung cancer
5.4. Integration of multi immune checkpoint blockade regimens with chemotherapy in second line treatment of gastric cancer
5.5. Emergence of cost effectiveness analyses influencing payer reimbursement decisions for first line PD-1 inhibitor treatments
5.6. Advancements in combination of CAR T cell therapy and checkpoint inhibition for refractory hematologic malignancies
5.7. Regulatory fast track designations accelerating approval of next generation CTLA-4 inhibitors with improved safety profiles
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immune Checkpoint Inhibitors Market, by Indication
8.1. Introduction
8.2. Bladder Cancer
8.3. Head And Neck Cancer
8.4. Melanoma
8.4.1. First Line
8.4.2. Second Line
8.5. Non Small Cell Lung Cancer
8.5.1. First Line
8.5.1.1. Combination Therapy
8.5.1.2. Monotherapy
8.5.2. Second Line
8.5.2.1. Combination Therapy
8.5.2.2. Monotherapy
8.6. Renal Cell Carcinoma
9. Immune Checkpoint Inhibitors Market, by Mechanism Of Action
9.1. Introduction
9.2. CTLA-4 Inhibitors
9.2.1. Ipilimumab
9.3. PD-1 Inhibitors
9.3.1. Cemiplimab
9.3.2. Nivolumab
9.3.3. Pembrolizumab
9.4. PD-L1 Inhibitors
9.4.1. Atezolizumab
9.4.2. Avelumab
9.4.3. Durvalumab
10. Immune Checkpoint Inhibitors Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Cancer Research Institutes
10.4. Hospitals
10.5. Specialty Clinics
11. Immune Checkpoint Inhibitors Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Subcutaneous
12. Americas Immune Checkpoint Inhibitors Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Immune Checkpoint Inhibitors Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Bristol-Myers Squibb Company
15.3.3. Roche Holding AG
15.3.4. AstraZeneca PLC
15.3.5. Pfizer Inc.
15.3.6. Merck KGaA
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. IMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. IMMUNE CHECKPOINT INHIBITORS MARKET: RESEARCHAI
FIGURE 24. IMMUNE CHECKPOINT INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 25. IMMUNE CHECKPOINT INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 26. IMMUNE CHECKPOINT INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 137. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 140. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 141. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 142. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 143. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 144. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 145. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 146. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 147. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 148. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 149. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 162. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 163. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 164. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 165. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 166. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 167. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 170. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 171. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 274. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 275. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 276. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 277. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 278. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 279. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 280. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 281. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 296. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 297. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 298. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 299. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 300. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 301. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 302. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 303. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 304. FRANCE IMMUN

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Immune Checkpoint Inhibitors market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck KGaA

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.48 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Immune Checkpoint Inhibitors for Cancer Market by Indication (Bladder Cancer, Head and Neck Cancer, Melanoma), Mechanism of Action (Ctla4 Inhibitor, Pd1 Inhibitor, Pdl1 Inhibitor), Treatment Modality, Therapy Line, End User - Global Forecast 2025-2030 - Product Image

Immune Checkpoint Inhibitors for Cancer Market by Indication (Bladder Cancer, Head and Neck Cancer, Melanoma), Mechanism of Action (Ctla4 Inhibitor, Pd1 Inhibitor, Pdl1 Inhibitor), Treatment Modality, Therapy Line, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2025-2033 - Product Image

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2025-2033

  • Report
  • 124 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
PD-1/PD-L1 Checkpoint Inhibitors Market by Product (Atezolizumab, Cemiplimab, Durvalumab), Indication (Hodgkin Lymphoma, Melanoma, Non Small Cell Lung Cancer), End User, Line of Therapy, Distribution Channel - Global Forecast 2025-2030 - Product Image

PD-1/PD-L1 Checkpoint Inhibitors Market by Product (Atezolizumab, Cemiplimab, Durvalumab), Indication (Hodgkin Lymphoma, Melanoma, Non Small Cell Lung Cancer), End User, Line of Therapy, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Checkpoint Inhibitors Market Report 2025 - Product Image

Checkpoint Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Market

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.